MeSH term
Frequency | Condition_Probility | Aged | 199 | 0.0 |
Humans | 858 | 0.0 |
Time Factors | 27 | 0.0 |
Aminoglycosides/*therapeutic use | 4 | 36.0 |
Animals | 69 | 0.0 |
Antibodies, Monoclonal/*therapeutic use | 12 | 3.0 |
Antigens, CD/*analysis | 93 | 11.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 38 | 37.0 |
Cell Death/drug effects | 3 | 1.0 |
Female | 310 | 0.0 |
Immunophenotyping | 247 | 8.0 |
Immunotoxins/*therapeutic use | 6 | 13.0 |
Mice | 47 | 0.0 |
Mice, SCID | 9 | 1.0 |
Neoplasm Transplantation | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 426 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Tumor Cells, Cultured | 86 | 0.0 |
Cell Division | 40 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
*Gene Expression Regulation, Leukemic | 3 | 3.0 |
Homeodomain Proteins/*genetics | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Retroviridae/genetics | 5 | 1.0 |
Antigens, CD/physiology | 4 | 1.0 |
Antigens, Differentiation, Myelomonocytic/physiology | 4 | 19.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Cells, Cultured | 83 | 0.0 |
*Immunomagnetic Separation | 2 | 11.0 |
Cell Culture Techniques | 2 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology/therapeutic use | 2 | 40.0 |
Karyotyping | 99 | 6.0 |
Male | 367 | 0.0 |
Middle Aged | 266 | 0.0 |
Monocytes/metabolism | 3 | 0.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Reference Values | 13 | 0.0 |
Up-Regulation | 3 | 0.0 |
Acute Disease | 118 | 5.0 |
Aminoglycosides | 4 | 30.0 |
Anti-Bacterial Agents/*pharmacology | 3 | 2.0 |
Antibodies, Monoclonal/*pharmacology | 5 | 2.0 |
Antineoplastic Agents/*pharmacology | 7 | 0.0 |
Monitoring, Physiologic | 2 | 2.0 |
Recurrence | 28 | 2.0 |
Adolescent | 151 | 0.0 |
Adult | 294 | 0.0 |
Aged, 80 and over | 64 | 0.0 |
Child | 108 | 0.0 |
Child, Preschool | 71 | 0.0 |
Gene Expression Regulation, Leukemic | 4 | 4.0 |
Neoplasm, Residual | 4 | 4.0 |
Tumor Stem Cells/*chemistry | 2 | 11.0 |
Dendritic Cells/*immunology | 6 | 2.0 |
Leukapheresis | 11 | 10.0 |
Membrane Glycoproteins/immunology | 2 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 107 | 0.0 |
Stem Cells/*immunology | 5 | 22.0 |
Blast Crisis/*genetics | 2 | 15.0 |
X Chromosome/*genetics | 2 | 0.0 |
*Aminoglycosides | 13 | 50.0 |
Antigens, CD/analysis/immunology | 6 | 12.0 |
Antigens, CD34/*analysis | 11 | 3.0 |
Antigens, Differentiation, Myelomonocytic/analysis/immunology | 6 | 37.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Drug Interactions | 3 | 0.0 |
P-Glycoprotein/*analysis | 2 | 11.0 |
Cell Division/drug effects | 23 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 18 | 10.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 19 | 4.0 |
Interleukin-3/pharmacology | 17 | 6.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
*Transcription Factors | 6 | 0.0 |
*Tumor Cells, Cultured/metabolism | 2 | 66.0 |
Base Sequence | 38 | 0.0 |
Cell Differentiation/*drug effects | 5 | 3.0 |
DNA Primers | 8 | 0.0 |
Flow Cytometry | 160 | 2.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Tretinoin/*pharmacology | 5 | 1.0 |
Amino Acid Sequence | 30 | 0.0 |
Antigens, CD/*genetics | 5 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/genetics | 3 | 12.0 |
Antigens, Differentiation, Myelomonocytic/genetics | 4 | 22.0 |
*Cell Adhesion Molecules | 11 | 5.0 |
Cloning, Molecular | 13 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Exons | 5 | 0.0 |
Gene Expression | 21 | 0.0 |
Genes, Structural/genetics | 2 | 0.0 |
Introns | 3 | 0.0 |
*Lectins | 14 | 7.0 |
Molecular Sequence Data | 55 | 0.0 |
Multigene Family | 4 | 0.0 |
Phylogeny | 5 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Sequence Homology, Amino Acid | 18 | 0.0 |
Antigens, CD13/analysis | 16 | 64.0 |
Antigens, CD34/analysis | 23 | 3.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 47 | 13.0 |
Bone Marrow Cells | 31 | 6.0 |
Cell Differentiation | 54 | 1.0 |
Cell Lineage | 19 | 4.0 |
Fetal Blood/cytology/immunology | 4 | 11.0 |
Hematopoietic Stem Cells/cytology/*immunology | 4 | 8.0 |
Infant | 47 | 0.0 |
Combined Modality Therapy | 12 | 1.0 |
Fetal Blood | 5 | 3.0 |
Remission Induction | 28 | 5.0 |
*Blast Crisis | 3 | 42.0 |
English Abstract | 83 | 0.0 |
Leukemia, Myeloid, Chronic/*pathology | 5 | 22.0 |
Parathyroid Hormone-Related Protein | 2 | 2.0 |
Anti-Bacterial Agents/*therapeutic use | 4 | 8.0 |
Antigens, CD/metabolism | 20 | 2.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 9 | 5.0 |
Antimetabolites, Antineoplastic/therapeutic use | 3 | 14.0 |
Antineoplastic Agents/therapeutic use | 8 | 2.0 |
Case-Control Studies | 4 | 0.0 |
Comparative Study | 74 | 0.0 |
Cytarabine/therapeutic use | 9 | 23.0 |
Fatal Outcome | 22 | 3.0 |
Hematopoietic Stem Cell Transplantation | 13 | 7.0 |
Leukemia, Myelocytic, Acute/*therapy | 4 | 17.0 |
Leukemic Infiltration | 2 | 15.0 |
Antigens, CD/immunology | 27 | 5.0 |
Antigens, Differentiation, Myelomonocytic/immunology | 13 | 27.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Drug Resistance, Neoplasm | 9 | 1.0 |
P-Glycoprotein | 2 | 4.0 |
Antibodies, Monoclonal/adverse effects/*therapeutic use | 4 | 10.0 |
Antibodies, Monoclonal | 48 | 1.0 |
Antigens, CD/analysis | 113 | 6.0 |
Bone Marrow Cells/immunology | 4 | 10.0 |
*Immunophenotyping | 38 | 21.0 |
Leukemia, B-Cell, Acute/immunology | 2 | 28.0 |
Leukemia, Myelocytic, Acute/immunology | 3 | 23.0 |
Leukemia, T-Cell, Acute/immunology | 3 | 25.0 |
Tumor Markers, Biological/analysis | 12 | 1.0 |
Antigens, CD56/*biosynthesis | 4 | 44.0 |
Biological Markers/analysis | 10 | 1.0 |
Bone Marrow Cells/immunology/pathology | 3 | 21.0 |
Leukemia, Myelocytic, Acute/*diagnosis/immunology | 2 | 40.0 |
Prognosis | 77 | 1.0 |
Treatment Outcome | 24 | 0.0 |
*Chromosomes, Human, Pair 12 | 5 | 1.0 |
*Chromosomes, Human, Pair 17 | 9 | 1.0 |
*Translocation, Genetic | 42 | 4.0 |
6-Mercaptopurine/administration & dosage | 4 | 21.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 27 | 5.0 |
Daunorubicin/administration & dosage | 11 | 30.0 |
Fusion Proteins, bcr-abl/genetics | 6 | 14.0 |
Leukemia, Myeloid, Philadelphia-Positive/*genetics | 2 | 7.0 |
Mitoxantrone/administration & dosage | 2 | 7.0 |
*Polyploidy | 2 | 7.0 |
Prednisolone/administration & dosage | 6 | 8.0 |
RNA, Messenger/genetics | 7 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
Antigens, Differentiation/analysis | 26 | 8.0 |
Bone Marrow/pathology | 38 | 9.0 |
Cell Differentiation/drug effects | 26 | 2.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
In Situ Hybridization, Fluorescence | 20 | 0.0 |
Leukemia, Lymphocytic, Acute/*pathology | 2 | 10.0 |
Leukemia, Myeloid/*pathology | 4 | 7.0 |
Philadelphia Chromosome | 4 | 8.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Chromosome Aberrations | 25 | 4.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 9 | 13.0 |
Gene Rearrangement, B-Lymphocyte, Light Chain | 2 | 9.0 |
RNA, Messenger/analysis | 13 | 0.0 |
*Tumor Cells, Cultured | 8 | 11.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
*Chromosomes, Human, Pair 8 | 9 | 3.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 7 | 3.0 |
*Trisomy | 8 | 7.0 |
Basophils/pathology | 2 | 50.0 |
Immunohistochemistry | 35 | 0.0 |
Mutation | 4 | 0.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 16 | 0.0 |
Antigens, CD14/analysis | 6 | 5.0 |
B-Lymphocytes/pathology | 3 | 3.0 |
Coculture Techniques | 2 | 0.0 |
Leukocytes, Mononuclear/immunology/*pathology | 2 | 33.0 |
Biopsy | 7 | 0.0 |
Cell Nucleus/pathology | 3 | 4.0 |
Cytoplasm/pathology | 3 | 11.0 |
*Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 4 | 33.0 |
HLA-DR Antigens/analysis | 33 | 5.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Antigens, CD3/analysis | 4 | 1.0 |
Antigens, CD56/*analysis | 4 | 12.0 |
Biological Markers | 24 | 1.0 |
Cytoplasm/immunology | 4 | 4.0 |
Killer Cells, Natural/*immunology | 5 | 1.0 |
Leukemia, Myeloid, Chronic/*immunology | 2 | 20.0 |
Leukemia, Myeloid, Philadelphia-Positive/immunology | 2 | 100.0 |
T-Lymphocytes/*immunology | 6 | 0.0 |
Antigens, CD/*immunology | 23 | 5.0 |
Antigens, Differentiation, Myelomonocytic/*immunology | 20 | 47.0 |
Cross-Linking Reagents | 3 | 0.0 |
HL-60 Cells | 19 | 3.0 |
Leukemia, Myeloid/*drug therapy | 4 | 33.0 |
Mice, Nude | 8 | 0.0 |
Antigens, CD/*metabolism | 18 | 2.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 16 | 28.0 |
Apoptosis | 3 | 0.0 |
Cell Survival | 6 | 0.0 |
In Vitro | 19 | 0.0 |
Killer Cells, Natural/cytology/immunology | 2 | 11.0 |
Receptors, Immunologic/*metabolism | 5 | 2.0 |
Blast Crisis/*pathology | 5 | 27.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
Diagnosis, Differential | 14 | 0.0 |
Leukemia, Lymphocytic, Acute/pathology | 2 | 20.0 |
Leukemia, Myeloid, Chronic-Phase/*pathology | 2 | 66.0 |
Bone Marrow Transplantation | 10 | 3.0 |
Disease Progression | 6 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 4 | 5.0 |
Genes, Immunoglobulin | 6 | 3.0 |
Glycophorin/analysis | 3 | 21.0 |
Methotrexate/therapeutic use | 3 | 4.0 |
Neoplasm Proteins/*analysis | 4 | 1.0 |
Peroxidase/analysis | 11 | 17.0 |
Transplantation, Homologous | 4 | 0.0 |
Vincristine/administration & dosage | 7 | 4.0 |
Hematopoietic Stem Cells/cytology/immunology | 4 | 12.0 |
Leukocyte Count | 16 | 1.0 |
Prospective Studies | 17 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Cross Reactions | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 9 | 5.0 |
*Proto-Oncogene Proteins | 4 | 0.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
Antigens, Differentiation, Myelomonocytic/genetics/*physiology | 2 | 40.0 |
Cell Membrane/metabolism | 5 | 0.0 |
Half-Life | 2 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 4 | 3.0 |
Chromosome Banding | 10 | 1.0 |
*Chromosome Deletion | 3 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Cell Line | 42 | 0.0 |
Chromosome Mapping | 16 | 0.0 |
DNA/genetics | 4 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
*Receptors, Cell Surface | 3 | 0.0 |
Signal Transduction | 3 | 0.0 |
Antigens, CD7/*metabolism | 4 | 40.0 |
Chromosomes, Human, Pair 21 | 4 | 3.0 |
Chromosomes, Human, Pair 8 | 7 | 5.0 |
Gene Rearrangement | 14 | 3.0 |
Leukemia, Myelocytic, Acute/genetics/immunology/*pathology | 3 | 50.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Translocation, Genetic/*genetics | 4 | 1.0 |
Antigens, CD13/analysis/immunology | 3 | 75.0 |
Clone Cells/immunology/pathology | 2 | 15.0 |
Leukemia, Lymphocytic, Acute, L1/*immunology/pathology | 3 | 60.0 |
Myeloid Cells/*immunology/pathology | 2 | 100.0 |
Oncogene Proteins, Fusion/genetics | 4 | 4.0 |
Reproducibility of Results | 5 | 0.0 |
Antigen Presentation | 6 | 1.0 |
Cell Separation/*methods | 7 | 4.0 |
Fetal Blood/*cytology | 11 | 5.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 15 | 12.0 |
Hematopoietic Stem Cell Mobilization | 3 | 3.0 |
Lymphocyte Culture Test, Mixed | 7 | 1.0 |
Monocytes/*cytology | 4 | 4.0 |
Leukemia, Promyelocytic, Acute/*drug therapy/pathology | 2 | 22.0 |
P-Glycoprotein/*metabolism | 3 | 3.0 |
Tretinoin/*pharmacology/therapeutic use | 2 | 14.0 |
Antibodies, Monoclonal/*diagnostic use | 7 | 3.0 |
Antigens, Neoplasm/*analysis | 25 | 6.0 |
*Genetic Vectors | 4 | 1.0 |
Antibodies, Bispecific/*pharmacology | 2 | 50.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
Leukemia, Myelocytic, Acute/*pathology | 7 | 17.0 |
Monocytes/immunology | 7 | 1.0 |
Phagocytosis | 5 | 1.0 |
Phosphorylation | 4 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Blotting, Northern | 12 | 0.0 |
Blotting, Southern | 14 | 0.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Genes, p53 | 2 | 0.0 |
Genes, ras | 2 | 0.0 |
Translocation, Genetic | 14 | 1.0 |
Antigens, CD34/*immunology | 12 | 16.0 |
Antigens, CD56/*immunology | 3 | 21.0 |
Cytokines/biosynthesis | 4 | 0.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
Interleukin-2/pharmacology | 3 | 0.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
Stem Cell Factor/pharmacology | 5 | 3.0 |
Follow-Up Studies | 10 | 0.0 |
Immunomagnetic Separation | 10 | 9.0 |
Antigens, Surface/*immunology | 6 | 3.0 |
Leukemia, Lymphocytic, Acute, L2/*immunology | 2 | 50.0 |
Antigens, CD34/metabolism | 3 | 1.0 |
Antigens, Surface/metabolism | 5 | 4.0 |
Cell Adhesion | 12 | 0.0 |
Cell Adhesion Molecules/*metabolism | 2 | 0.0 |
Cytokines/metabolism | 2 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Leukemia, Lymphocytic, Acute/*immunology | 3 | 11.0 |
Pericarditis/*etiology | 2 | 100.0 |
Antigens, CD7/*analysis | 6 | 24.0 |
Cytarabine/administration & dosage | 8 | 9.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Antigens, CD/chemistry/*genetics | 2 | 15.0 |
Antigens, Differentiation, Myelomonocytic/chemistry/*genetics | 2 | 66.0 |
Bone Marrow/metabolism | 3 | 2.0 |
COS Cells | 4 | 0.0 |
Chromosomes, Human, Pair 19 | 3 | 1.0 |
Erythrocytes/metabolism | 4 | 2.0 |
Evolution, Molecular | 2 | 0.0 |
Mice, Inbred BALB C | 8 | 0.0 |
Models, Genetic | 2 | 0.0 |
*Multigene Family | 5 | 0.0 |
N-Acetylneuraminic Acid/metabolism | 3 | 20.0 |
Point Mutation | 3 | 0.0 |
Protein Binding | 9 | 0.0 |
Rats | 3 | 0.0 |
Antibiotics, Antineoplastic/therapeutic use | 3 | 17.0 |
Clinical Trials | 7 | 0.0 |
Cytogenetics | 6 | 7.0 |
Vidarabine/analogs & derivatives/therapeutic use | 2 | 40.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Cytokines/*pharmacology | 9 | 2.0 |
Growth Substances/*pharmacology | 3 | 0.0 |
Hematopoietic Stem Cell Mobilization/*methods | 3 | 5.0 |
*Hematopoietic Stem Cell Transplantation | 16 | 4.0 |
Interleukin-6/pharmacology | 6 | 2.0 |
Mice, Inbred NOD | 4 | 1.0 |
Thrombopoietin/pharmacology | 2 | 3.0 |
Age Factors | 6 | 0.0 |
Clone Cells/pathology | 2 | 3.0 |
Macrophage-1 Antigen/analysis | 4 | 8.0 |
Phenotype | 88 | 0.0 |
Analysis of Variance | 4 | 0.0 |
*Antigens, CD34 | 2 | 2.0 |
Fetal Blood/*cytology/immunology | 4 | 17.0 |
Lymphocyte Count | 3 | 0.0 |
Spleen/immunology | 2 | 1.0 |
Basophils/cytology | 2 | 66.0 |
*Genes, abl | 2 | 7.0 |
Antigens, Neoplasm/analysis | 18 | 5.0 |
Antigens, CD/*physiology | 6 | 1.0 |
Antigens, Differentiation, Myelomonocytic/*physiology | 6 | 19.0 |
Cell Division/physiology | 3 | 0.0 |
Leukemia, Myeloid/*immunology/*pathology | 2 | 50.0 |
Receptors, Immunologic/*physiology | 3 | 1.0 |
Leukemia, Myelocytic, Acute/*drug therapy | 7 | 33.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Fetus | 2 | 0.0 |
Pregnancy | 16 | 0.0 |
*Tissue Donors | 3 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 4 | 12.0 |
Leukocytes, Mononuclear/metabolism | 3 | 1.0 |
Survival Analysis | 22 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Translocation, Genetic/genetics | 3 | 3.0 |
Down Syndrome/*complications | 2 | 14.0 |
B-Lymphocytes/*immunology/pathology | 2 | 4.0 |
Reference Standards | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Leukemia, Myeloid/*metabolism | 2 | 6.0 |
Antigens, CD14/metabolism | 2 | 1.0 |
Carcinogens/pharmacology | 2 | 2.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
K562 Cells | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Antigens, Surface/immunology | 4 | 2.0 |
*Immunotherapy | 3 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 2 | 3.0 |
Cytarabine/*administration & dosage | 3 | 33.0 |
Etoposide/*administration & dosage | 3 | 50.0 |
*Alternative Splicing | 2 | 0.0 |
*Chromosomes, Human, Pair 19 | 8 | 2.0 |
Organ Specificity | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
*Membrane Proteins | 2 | 0.0 |
Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use | 2 | 20.0 |
United States | 2 | 0.0 |
HLA-D Antigens/analysis | 4 | 7.0 |
Antigens, CD13/*immunology | 2 | 50.0 |
Peroxidase/metabolism | 5 | 3.0 |
Hematopoietic Stem Cells/immunology/*metabolism | 5 | 27.0 |
Lymphocytes/immunology | 7 | 1.0 |
Flow Cytometry/*methods | 15 | 6.0 |
Incidence | 2 | 0.0 |
Sensitivity and Specificity | 12 | 0.0 |
Cytogenetic Analysis | 3 | 2.0 |
Membrane Glycoproteins/*physiology | 2 | 0.0 |
Antigens, CD19/analysis | 3 | 3.0 |
Antigens, CD2/analysis | 2 | 5.0 |
Antigens, CD56/analysis | 8 | 12.0 |
Leukemia, Myelocytic, Acute/*immunology | 5 | 14.0 |
Neoplasm, Residual/*diagnosis | 2 | 4.0 |
*Chromosomes, Human, Pair 11 | 11 | 1.0 |
DNA-Binding Proteins/genetics | 6 | 0.0 |
Genotype | 9 | 0.0 |
*Proto-Oncogenes | 8 | 1.0 |
Antigens, CD4/analysis | 4 | 0.0 |
Antigens, CD45/analysis | 9 | 3.0 |
Leukemia/immunology/*pathology | 3 | 37.0 |
Serine Endopeptidases/analysis | 2 | 5.0 |
T-Lymphocytes/immunology | 10 | 0.0 |
Transfection | 12 | 0.0 |
Apoptosis/drug effects | 5 | 0.0 |
Granulocytes/metabolism | 3 | 7.0 |
Kinetics | 5 | 0.0 |
*Chromosomes, Human, Pair 10 | 4 | 2.0 |
T-Lymphocytes/immunology/pathology | 3 | 5.0 |
DNA, Complementary | 3 | 0.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Receptors, Retinoic Acid/genetics | 4 | 4.0 |
*Bone Marrow Transplantation | 5 | 1.0 |
*Chromosomes, Human, Pair 16 | 4 | 1.0 |
*Chromosomes, Human, Pair 21 | 8 | 4.0 |
Hemoglobins/analysis | 2 | 0.0 |
Platelet Count | 3 | 0.0 |
Treatment Failure | 3 | 1.0 |
*Chromosomes, Human, Pair 9 | 6 | 2.0 |
Peroxidase/*metabolism | 4 | 6.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
Antigens, CD/biosynthesis | 8 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 13 | 2.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Neoplasms, Second Primary/*etiology | 3 | 42.0 |
*Monosomy | 4 | 12.0 |
Lymphocyte Activation | 10 | 0.0 |
Macrophages/*physiology | 3 | 3.0 |
Antigens, CD3/*metabolism | 2 | 4.0 |
Hematopoietic Stem Cells/*cytology | 14 | 6.0 |
Infant, Newborn | 33 | 0.0 |
Immunophenotyping/*standards | 2 | 16.0 |
Antigens, Differentiation, Myelomonocytic/*chemistry/genetics/*metabolism | 2 | 100.0 |
CHO Cells | 3 | 0.0 |
Carbohydrate Conformation | 3 | 2.0 |
Carbohydrate Sequence | 6 | 1.0 |
Glycosylation | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Ligands | 3 | 0.0 |
Japan | 3 | 0.0 |
Bone Marrow/embryology | 3 | 12.0 |
Bone Marrow Cells/*metabolism | 3 | 6.0 |
*Cell Line, Tumor | 2 | 15.0 |
Microscopy, Electron | 29 | 1.0 |
*Mutation | 5 | 0.0 |
Polymerase Chain Reaction | 31 | 0.0 |
U937 Cells | 3 | 0.0 |
Bone Marrow Cells/*immunology | 5 | 18.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Colony-Stimulating Factors/pharmacology | 5 | 11.0 |
Antigens, Surface/*blood | 2 | 13.0 |
Antigens, CD34/blood | 2 | 3.0 |
Blood | 2 | 1.0 |
Bone Marrow Cells/*pathology | 2 | 8.0 |
Cytoplasmic Granules/*pathology | 2 | 28.0 |
Transcription Factors/genetics | 6 | 0.0 |
Zinc Fingers | 3 | 0.0 |
Cytotoxicity, Immunologic | 8 | 0.0 |
Killer Cells, Natural/chemistry/*pathology | 2 | 33.0 |
Leukemia, Myelomonocytic, Chronic/*pathology | 2 | 50.0 |
Tumor Stem Cells/chemistry/*pathology | 2 | 40.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Gene Expression Regulation, Leukemic/*drug effects | 2 | 5.0 |
Tetradecanoylphorbol Acetate/pharmacology | 15 | 0.0 |
Flow Cytometry/methods | 16 | 6.0 |
Histamine/metabolism | 2 | 5.0 |
Integrin alpha4 | 4 | 10.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Chromosome Disorders | 14 | 4.0 |
Leukemia, Myeloid/diagnosis/*immunology | 2 | 66.0 |
Antigens, Surface/analysis | 36 | 8.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
Receptors, IgG/analysis | 5 | 7.0 |
Antigens, CD/blood | 7 | 2.0 |
Infant, Premature | 4 | 3.0 |
*Lymphocyte Activation | 5 | 0.0 |
Antibodies, Monoclonal/immunology/*therapeutic use | 2 | 6.0 |
Leukemia, Myeloid/immunology/*therapy | 4 | 57.0 |
Antibodies, Monoclonal/*immunology | 7 | 0.0 |
Cell Cycle | 5 | 0.0 |
DNA Fragmentation | 3 | 0.0 |
*Antigens, CD | 17 | 2.0 |
Antigens, CD34/*blood | 4 | 5.0 |
Integrin alpha4beta1 | 2 | 2.0 |
Stem Cells/immunology | 3 | 9.0 |
Lectins/*genetics | 2 | 22.0 |
Tissue Distribution | 4 | 0.0 |
Antigens, CD/*biosynthesis/immunology | 2 | 8.0 |
Leukemia/*immunology | 2 | 5.0 |
Tumor Markers, Biological | 4 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
Fetal Blood/cytology | 8 | 4.0 |
Hematopoiesis | 6 | 2.0 |
T-Lymphocytes | 3 | 1.0 |
Gene Transfer Techniques | 2 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Antigens, CD13/*analysis | 2 | 40.0 |
Cell Lineage/*immunology | 4 | 36.0 |
Dendritic Cells/*cytology/immunology | 3 | 6.0 |
Hematopoietic Stem Cells/*cytology/*immunology | 4 | 16.0 |
Monocytes/*cytology/immunology | 2 | 10.0 |
Cell Division/immunology | 4 | 1.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
Cell Adhesion Molecules/*analysis | 2 | 1.0 |
Colony-Forming Units Assay | 30 | 5.0 |
Integrins/analysis | 2 | 4.0 |
Epitopes/*immunology | 2 | 0.0 |
Blood Cell Count/*methods | 2 | 22.0 |
HLA-DR Antigens/analysis/immunology | 2 | 10.0 |
Leukemia, Myelocytic, Acute/*genetics | 7 | 6.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Antigens, CD34/*metabolism | 3 | 2.0 |
Interleukin-4/pharmacology | 4 | 1.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
Lymphocyte Subsets | 3 | 1.0 |
Naphthol AS D Esterase/metabolism | 2 | 22.0 |
Receptors, IgG/metabolism | 2 | 2.0 |
Antigens, CD/genetics | 2 | 1.0 |
Immunoglobulins/*genetics | 2 | 4.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
Receptors, Immunologic/genetics | 2 | 4.0 |
Binding Sites | 4 | 0.0 |
Immunoglobulins/*metabolism | 2 | 3.0 |
Hematopoietic Stem Cells/*immunology | 22 | 15.0 |
Immunoconjugates/*therapeutic use | 2 | 16.0 |
Leukemia, Myeloid/immunology/pathology/*therapy | 2 | 100.0 |
Tumor Stem Cells/*immunology | 4 | 17.0 |
ADP-ribosyl Cyclase | 22 | 4.0 |
Antigens, Surface/*analysis | 20 | 10.0 |
*Flow Cytometry | 9 | 5.0 |
NAD+ Nucleosidase/analysis | 2 | 4.0 |
Tretinoin/*therapeutic use | 2 | 9.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Antigens, CD/*biosynthesis | 6 | 3.0 |
Antigens, Differentiation/*biosynthesis | 2 | 6.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 2 | 2.0 |
*Philadelphia Chromosome | 4 | 5.0 |
Vincristine/therapeutic use | 3 | 7.0 |
Oxides/*pharmacology | 2 | 8.0 |
Antigens, CD7/analysis | 2 | 10.0 |
Leukemia, Myelocytic, Acute/*immunology/pathology | 2 | 20.0 |
Antibodies, Monoclonal/*administration & dosage | 2 | 6.0 |
Survival Rate | 18 | 0.0 |
Erythrocytes/immunology | 2 | 0.0 |
Granulocytes/immunology | 3 | 5.0 |
Linkage (Genetics) | 3 | 0.0 |
Cell Differentiation/physiology | 4 | 0.0 |
Antigens, CD14/biosynthesis | 3 | 4.0 |
Macrophage Colony-Stimulating Factor/*pharmacology | 3 | 7.0 |
Receptors, IgG/biosynthesis | 2 | 7.0 |
Culture Techniques/methods | 3 | 5.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 5.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
N-Acetylneuraminic Acid/*metabolism | 3 | 18.0 |
Bone Marrow/*immunology | 11 | 18.0 |
Fetal Blood/*immunology | 6 | 7.0 |
HLA-DR Antigens/immunology | 4 | 1.0 |
Leukocytes, Mononuclear/immunology | 4 | 1.0 |
Lymphocyte Subsets/immunology | 4 | 2.0 |
Antigens, CD34/*blood/immunology | 2 | 66.0 |
Cell Separation | 29 | 2.0 |
Immunomagnetic Separation/methods | 2 | 18.0 |
Stem Cells/cytology/immunology | 3 | 16.0 |
Antigens, CD14 | 15 | 5.0 |
3T3 Cells | 2 | 0.0 |
Molecular Weight | 4 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 6 | 19.0 |
Antigens, CD/genetics/*metabolism | 2 | 2.0 |
Antigens, Differentiation, Myelomonocytic/genetics/*metabolism | 2 | 40.0 |
Cell Adhesion Molecules/genetics/*metabolism | 2 | 4.0 |
Interleukin-2/*therapeutic use | 2 | 1.0 |
Leukemia, Myelocytic, Acute/immunology/*therapy | 2 | 25.0 |
Immunotherapy | 4 | 1.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Leukemia, Myeloid/*therapy | 3 | 20.0 |
Retrospective Studies | 13 | 0.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Immunophenotyping/methods | 6 | 12.0 |
DNA/analysis | 3 | 0.0 |
Immunophenotyping/*methods | 5 | 7.0 |
*Ploidies | 3 | 4.0 |
Antigens, Differentiation, Myelomonocytic/biosynthesis | 4 | 8.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
Receptors, Antigen, T-Cell/genetics | 4 | 4.0 |
Tumor Markers, Biological/*immunology | 2 | 8.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Cell Line, Transformed | 4 | 0.0 |
Cytokines/pharmacology | 7 | 1.0 |
*Chromosomes, Human, Pair 22 | 3 | 1.0 |
Leukemia, Lymphocytic, Acute/*genetics/immunology/pathology | 3 | 100.0 |
Receptors, Cytokine/metabolism | 2 | 2.0 |
Cell Size | 3 | 1.0 |
Leukemia, Myelocytic, Acute/immunology/*pathology | 4 | 30.0 |
*Tumor Markers, Biological | 3 | 1.0 |
*Chromosome Aberrations | 16 | 2.0 |
DNA, Neoplasm/analysis | 10 | 1.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Peroxidase/*immunology | 3 | 9.0 |
B-Lymphocytes/immunology/pathology | 2 | 4.0 |
DNA Primers/genetics | 2 | 0.0 |
Cell Differentiation/drug effects/immunology | 2 | 2.0 |
Leukemia, Myeloid/immunology/*pathology | 2 | 22.0 |
Receptors, IgG/*immunology | 3 | 9.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Hematopoietic Cell Growth Factors/pharmacology | 6 | 7.0 |
Cell Differentiation/immunology | 13 | 4.0 |
Stem Cells/cytology/*immunology | 2 | 28.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Antigens, CD14/blood | 2 | 6.0 |
Antigens, Differentiation, Myelomonocytic/blood | 5 | 31.0 |
Membrane Glycoproteins/blood | 2 | 6.0 |
Cell Differentiation/drug effects/physiology | 3 | 3.0 |
Tretinoin/pharmacology | 10 | 3.0 |
Etoposide/therapeutic use | 2 | 11.0 |
Bone Marrow Cells/*cytology | 3 | 6.0 |
Leukemia, Myeloid/*genetics/immunology | 2 | 33.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Hematopoiesis/drug effects | 7 | 8.0 |
Injections, Intravenous | 2 | 0.0 |
Antigens, CD34 | 78 | 12.0 |
Blood Cell Count | 4 | 1.0 |
*Hematopoiesis | 9 | 4.0 |
*Hematopoietic Stem Cell Mobilization | 2 | 3.0 |
Hematopoietic Stem Cells/pathology | 4 | 10.0 |
Transplantation, Autologous | 8 | 2.0 |
Antigens, Differentiation/*analysis | 14 | 7.0 |
Cell Survival/drug effects | 3 | 0.0 |
Hematopoietic Stem Cells/*drug effects/immunology | 2 | 40.0 |
NAD+ Nucleosidase/*analysis | 2 | 8.0 |
Eosinophils/cytology | 2 | 14.0 |
HLA-DR Antigens/blood | 3 | 5.0 |
Hematopoietic Stem Cells/*cytology/immunology | 10 | 12.0 |
Macrophages/cytology | 2 | 2.0 |
Mast Cells/*cytology/immunology | 2 | 66.0 |
Antigens, CD/*analysis/biosynthesis/genetics | 2 | 66.0 |
Leukemia, Lymphocytic, Acute/*immunology/pathology | 2 | 22.0 |
Leukemia, Myeloid/*immunology/pathology | 2 | 14.0 |
Myelodysplastic Syndromes/*immunology/pathology | 2 | 66.0 |
*Leukapheresis | 4 | 11.0 |
Monocytes/*immunology | 12 | 2.0 |
Chromosomes, Human, Pair 21/*genetics | 4 | 4.0 |
Chromosomes, Human, Pair 8/*genetics | 4 | 3.0 |
Predictive Value of Tests | 10 | 0.0 |
Schizophrenia/complications | 2 | 40.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 3 | 5.0 |
Hematopoietic Stem Cell Mobilization/methods | 2 | 11.0 |
Neoplasms/*therapy | 3 | 2.0 |
Stem Cell Factor | 6 | 6.0 |
Stromal Cells/cytology | 2 | 4.0 |
Chimera | 2 | 1.0 |
*Gene Transfer Techniques | 3 | 0.0 |
*Retroviridae | 2 | 8.0 |
Fetus/*immunology | 2 | 4.0 |
Genetic Vectors | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
Transduction, Genetic | 3 | 0.0 |
Killer Cells, Natural/*pathology | 3 | 10.0 |
Leukemia, Myeloid, Philadelphia-Positive/*pathology | 3 | 33.0 |
Neoplasm Proteins/analysis | 5 | 1.0 |
Tumor Stem Cells/*pathology | 2 | 7.0 |
*Killer Cells, Natural | 2 | 9.0 |
Antigens, CD | 10 | 7.0 |
Cell Survival/immunology | 2 | 3.0 |
HTLV-I Infections/*immunology | 2 | 12.0 |
Peroxidase/*genetics | 2 | 3.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Antigens, Differentiation/biosynthesis | 2 | 3.0 |
Rabbits | 2 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Blast Crisis | 4 | 11.0 |
Bone Marrow/immunology/pathology | 5 | 13.0 |
*Chromosomes, Human, Pair 1 | 3 | 0.0 |
*Chromosomes, Human, Pair 7 | 5 | 1.0 |
*Inversion, Chromosome | 2 | 2.0 |
Bone Marrow Cells/*immunology/pathology | 3 | 50.0 |
Radioimmunotherapy | 2 | 18.0 |
Recombinant Proteins | 2 | 0.0 |
B-Lymphocytes/immunology | 4 | 0.0 |
Hematopoietic Stem Cells/immunology/pathology | 3 | 16.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Hematopoiesis/physiology | 4 | 9.0 |
Antigens, Neoplasm/*metabolism | 4 | 4.0 |
Disease-Free Survival | 8 | 0.0 |
Leukemia, Lymphocytic, Acute, L1/*immunology | 2 | 33.0 |
Antigens, Differentiation/blood | 2 | 18.0 |
*Blood Transfusion, Autologous | 2 | 8.0 |
Hematologic Neoplasms/*therapy | 2 | 7.0 |
Bone Marrow/*pathology | 9 | 6.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Leukemia, Myeloid/pathology | 3 | 13.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/immunology | 2 | 7.0 |
Cyclophosphamide/pharmacology | 2 | 5.0 |
Remission Induction/methods | 2 | 8.0 |
Hematopoietic Stem Cells/immunology | 6 | 7.0 |
Antibodies, Monoclonal/therapeutic use | 4 | 2.0 |
Leukemia, Promyelocytic, Acute/*pathology | 3 | 14.0 |
Antigens, CD/*analysis/*biosynthesis | 2 | 40.0 |
*Gestational Age | 3 | 5.0 |
HLA-DR Antigens/analysis/biosynthesis | 2 | 40.0 |
Embryonic and Fetal Development/physiology | 2 | 2.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Proto-Oncogene Protein c-kit/biosynthesis | 2 | 13.0 |
*Cell Differentiation | 4 | 1.0 |
Cell Count | 9 | 0.0 |
Cell Movement | 2 | 0.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Monocytes/cytology/*immunology | 2 | 5.0 |
Sialic Acids/*metabolism | 3 | 16.0 |
Culture Media | 2 | 0.0 |
Tumor Cells, Cultured/*pathology | 2 | 10.0 |
Multivariate Analysis | 8 | 0.0 |
Antigens, Differentiation, Myelomonocytic/*genetics | 2 | 28.0 |
Cell Adhesion Molecules/*genetics | 2 | 2.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Leukemia, Myeloid/metabolism | 2 | 16.0 |
Rosette Formation | 2 | 0.0 |
Bone Marrow/immunology | 11 | 8.0 |
*Gene Rearrangement, T-Lymphocyte | 4 | 8.0 |
*Genes, Immunoglobulin | 3 | 1.0 |
Neprilysin/analysis | 7 | 13.0 |
Leukemia, Myeloid/*immunology | 4 | 10.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 2 | 1.0 |
Cryopreservation | 2 | 1.0 |
Immunotoxins/*pharmacology | 2 | 4.0 |
Plant Proteins/*pharmacology | 3 | 15.0 |
Recombinant Proteins/pharmacology | 17 | 0.0 |
Proto-Oncogene Protein c-kit/*metabolism | 2 | 4.0 |
Antibodies, Monoclonal/immunology | 15 | 0.0 |
Antigens, CD14/*analysis | 3 | 6.0 |
*Phagocytosis | 3 | 2.0 |
Daunorubicin/therapeutic use | 3 | 21.0 |
Leukemia, Lymphocytic, Acute, L1/drug therapy/*immunology | 2 | 25.0 |
Leukemia, Myeloid/*genetics/*immunology | 2 | 100.0 |
Clone Cells/cytology | 2 | 10.0 |
Leukocytes, Mononuclear/cytology/immunology | 4 | 9.0 |
Proportional Hazards Models | 5 | 0.0 |
Risk Factors | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 15 | 1.0 |
Drug Synergism | 3 | 0.0 |
Growth Substances/pharmacology | 4 | 2.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Granulocyte Colony-Stimulating Factor/*administration & dosage | 2 | 7.0 |
Leukemia, Myelocytic, Acute/genetics/*pathology | 2 | 25.0 |
Antibodies, Monoclonal/diagnostic use | 22 | 2.0 |
Leukemia/metabolism | 2 | 8.0 |
Peroxidase/*analysis | 3 | 15.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Leukemia, Myeloid, Chronic/genetics/immunology/*pathology | 3 | 75.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Interleukin-1/secretion | 2 | 4.0 |
Membrane Glycoproteins/analysis | 6 | 2.0 |
Down-Regulation | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 4 | 1.0 |
Skin/*pathology | 3 | 3.0 |
Leukemia/*diagnosis | 3 | 30.0 |
Clone Cells | 9 | 0.0 |
Hematopoietic Stem Cells/*chemistry/cytology | 2 | 28.0 |
HLA Antigens/analysis | 3 | 1.0 |
Leukemia, Monocytic, Acute/classification | 2 | 100.0 |
Leukemia, Myelocytic, Acute/classification | 2 | 100.0 |
Killer Cells, Natural/*cytology/immunology | 2 | 28.0 |
Stimulation, Chemical | 3 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Acid Phosphatase/metabolism | 2 | 3.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
Epirubicin/administration & dosage | 2 | 5.0 |
Infusions, Intravenous | 4 | 0.0 |
Histamine Release | 4 | 6.0 |
*Chromosome Mapping | 3 | 0.0 |
T-Lymphocytes/pathology | 4 | 3.0 |
Chromosome Deletion | 3 | 0.0 |
*Chromosome Disorders | 3 | 4.0 |
Chromosomes, Human, Pair 11 | 4 | 1.0 |
Inversion, Chromosome | 3 | 4.0 |
Bone Marrow/immunology/*pathology | 5 | 29.0 |
Etoposide/administration & dosage | 7 | 6.0 |
*Radioimmunotherapy | 2 | 7.0 |
Leukemia, Myelocytic, Acute/*genetics/immunology | 2 | 33.0 |
Plastics | 2 | 6.0 |
Antigens, CD13/biosynthesis | 2 | 28.0 |
Bone Marrow/immunology/metabolism | 2 | 28.0 |
*Gene Rearrangement | 4 | 1.0 |
Cell Adhesion/drug effects | 3 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Bone Marrow/chemistry/immunology/*pathology | 2 | 100.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Histocytochemistry | 18 | 2.0 |
Dendritic Cells/*pathology | 2 | 5.0 |
Antigens, CD2/*metabolism | 2 | 6.0 |
*Apoptosis | 2 | 0.0 |
Fusion Proteins, bcr-abl/metabolism | 2 | 12.0 |
Cell Adhesion Molecules/analysis | 8 | 5.0 |
Integrin alphaXbeta2/analysis | 2 | 13.0 |
*Chromosomes, Human, Pair 4 | 4 | 1.0 |
HLA Antigens/*analysis | 2 | 0.0 |
Proto-Oncogene Protein c-kit/analysis | 2 | 4.0 |
Chromosomes, Human, Pair 16 | 2 | 1.0 |
Chromosomes, Human, Pair 9 | 7 | 4.0 |
Fusion Proteins, bcr-abl/*genetics | 4 | 5.0 |
Antigens, CD3/genetics | 2 | 14.0 |
Chromosome Aberrations/pathology | 2 | 22.0 |
Gene Rearrangement, T-Lymphocyte | 6 | 5.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Lymph Nodes/pathology | 4 | 1.0 |
In Situ Hybridization | 4 | 0.0 |
*Megakaryocytes | 2 | 16.0 |
Cell Separation/methods | 3 | 1.0 |
Chromosomes, Human, Pair 22 | 5 | 3.0 |
Hematopoietic Stem Cells/*pathology | 4 | 5.0 |
Bone Marrow/ultrastructure | 2 | 15.0 |
Myelodysplastic Syndromes/*genetics/pathology | 2 | 13.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Transcription, Genetic | 5 | 0.0 |
Leukemia, Monocytic, Acute/*pathology | 3 | 23.0 |
Leukemia, Myelomonocytic, Acute/*pathology | 2 | 22.0 |
Liposomes | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics/immunology/pathology | 3 | 100.0 |
Antigens, Neoplasm/*immunology | 3 | 1.0 |
Lymphoma/pathology | 2 | 7.0 |
HLA-DR Antigens/biosynthesis | 3 | 3.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Cytokines/*biosynthesis/genetics | 2 | 2.0 |
B-Lymphocytes/*immunology | 5 | 0.0 |
Cell Communication/immunology | 2 | 2.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
Antigens, CD/*analysis/immunology | 6 | 20.0 |
Erythrocytes | 2 | 4.0 |
Fluorescein-5-isothiocyanate | 2 | 1.0 |
Leukocytes/*immunology | 2 | 1.0 |
Phycoerythrin | 3 | 15.0 |
Myelodysplastic Syndromes/immunology/*pathology | 2 | 50.0 |
Trisomy | 4 | 3.0 |
Asthma/*immunology | 2 | 2.0 |
Macrophages, Alveolar/*immunology | 3 | 7.0 |
Liver/cytology/*embryology | 2 | 20.0 |
Radiation Chimera | 2 | 4.0 |
Killer Cells, Natural/cytology/*immunology | 2 | 7.0 |
Asparaginase/administration & dosage | 3 | 14.0 |
Leukemia, Lymphocytic, Acute/*genetics | 4 | 4.0 |
Myelodysplastic Syndromes/pathology | 2 | 28.0 |
Monocytes/*metabolism | 2 | 0.0 |
Solubility | 2 | 0.0 |
Blast Crisis/*immunology | 3 | 75.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 3 | 11.0 |
Leukemia/genetics/immunology/*pathology | 2 | 40.0 |
HLA-DR Antigens/*metabolism | 2 | 3.0 |
Monocytes/cytology | 2 | 1.0 |
Drug Resistance | 4 | 0.0 |
False Positive Reactions | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
*Bone Marrow Cells | 27 | 10.0 |
Stem Cells | 2 | 1.0 |
Cell Movement/drug effects | 2 | 0.0 |
*Chromosomes, Human, Pair 6 | 2 | 0.0 |
Stem Cells/pathology | 2 | 10.0 |
Blood Cells/*immunology | 2 | 10.0 |
HIV-1/*immunology | 2 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Leukocytes, Mononuclear/*immunology | 6 | 3.0 |
Gestational Age | 2 | 0.0 |
Hematopoietic Stem Cells/metabolism | 3 | 2.0 |
Oncogene Proteins, Fusion/analysis | 2 | 25.0 |
Myelin-Associated Glycoprotein/genetics | 2 | 40.0 |
Lymphoma, Non-Hodgkin/*therapy | 3 | 27.0 |
Antigens, Differentiation, Myelomonocytic | 4 | 15.0 |
*Drug Resistance, Multiple | 2 | 1.0 |
Interferon-alpha/*biosynthesis | 2 | 11.0 |
Antigens, CD/*blood | 10 | 5.0 |
Fetal Blood/immunology | 2 | 2.0 |
Lymphoma, Non-Hodgkin/immunology/pathology | 2 | 20.0 |
Neoplasm Staging | 3 | 0.0 |
Leukemia, Nonlymphocytic, Acute/*genetics | 3 | 37.0 |
Leukemia, Lymphocytic, Acute/immunology/*pathology | 3 | 33.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Prednisone/administration & dosage | 3 | 3.0 |
Leukemia, B-Cell, Chronic/*immunology/pathology | 2 | 12.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 5 | 7.0 |
Macrophages/*immunology | 6 | 2.0 |
Tumor Stem Cell Assay | 8 | 4.0 |
Bone Marrow/*immunology/pathology | 2 | 11.0 |
Carboxylic Ester Hydrolases/metabolism | 2 | 10.0 |
Acid Phosphatase/analysis | 2 | 2.0 |
Leukemia, Myelocytic, Acute/immunology/pathology | 3 | 42.0 |
N-Glycosyl Hydrolases/analysis | 2 | 7.0 |
Periodic Acid-Schiff Reaction | 2 | 7.0 |
Antigens, Neoplasm/immunology | 3 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Erythrocytes/physiology | 2 | 5.0 |
Up-Regulation/immunology | 2 | 1.0 |
*Gene Expression Regulation | 4 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 8 | 4.0 |
Erythropoietin/pharmacology | 4 | 3.0 |
Anemia/etiology | 3 | 9.0 |
Erythropoiesis | 2 | 2.0 |
Blood Component Removal | 2 | 4.0 |
Megakaryocytes/*immunology | 2 | 40.0 |
HLA-DR Antigens/*analysis | 8 | 4.0 |
Leukemia/genetics/*pathology | 2 | 28.0 |
*Oncogenes | 2 | 0.0 |
Macrophage-1 Antigen/metabolism | 2 | 2.0 |
Antigens, CD13/*blood | 2 | 100.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Antigens, Differentiation, Myelomonocytic/*blood | 4 | 22.0 |
Fluorescent Antibody Technique | 23 | 0.0 |
Leukemia, Myeloid, Chronic/immunology/*pathology | 2 | 22.0 |
Receptors, IgG/*analysis | 3 | 10.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
T-Lymphocytes/immunology/*pathology | 2 | 5.0 |
Administration, Oral | 2 | 0.0 |
Antigens, CD19 | 8 | 4.0 |
Antigens, CD2 | 3 | 0.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
Dexamethasone/administration & dosage | 2 | 6.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 3 | 5.0 |
Thymidine/metabolism | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Leukemia, Megakaryocytic, Acute/*pathology | 2 | 25.0 |
Lung | 2 | 2.0 |
Cranial Irradiation | 2 | 25.0 |
Myelofibrosis/*pathology | 2 | 50.0 |
*Genes, ras | 2 | 0.0 |
Blast Crisis/pathology | 2 | 20.0 |
Leukemia, Myeloid/genetics/*pathology | 2 | 16.0 |
Megakaryocytes/pathology | 2 | 11.0 |
Antigens, CD4/*analysis | 3 | 1.0 |
Antigens, CD15/analysis | 3 | 10.0 |
Myelodysplastic Syndromes/*pathology | 2 | 6.0 |
*Genes, Structural | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Leukemia, Myeloid/*genetics/immunology/pathology | 2 | 100.0 |
Microscopy, Immunoelectron | 4 | 0.0 |
Chromosomes, Human, Pair 5 | 2 | 1.0 |
Leukemia, Myelocytic, Acute/blood | 2 | 33.0 |
Light | 6 | 2.0 |
Antigens, CD/*analysis/blood | 5 | 35.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
Antigens, CD40 | 2 | 3.0 |
Receptors, Virus/*physiology | 2 | 5.0 |
Hematopoietic Stem Cells/*cytology/drug effects/immunology | 3 | 17.0 |
Proto-Oncogene Protein c-kit | 10 | 12.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Leukemia, Myeloid/*immunology/therapy | 2 | 66.0 |
*Phenotype | 2 | 0.0 |
Antigens, CD/analysis/*blood | 2 | 40.0 |
Antigens, CD7 | 15 | 13.0 |
Interleukin-3/*pharmacology | 11 | 8.0 |
Leukemia/classification/immunology/*pathology | 2 | 100.0 |
*Cell Separation | 3 | 21.0 |
Gene Expression Regulation, Leukemic/drug effects | 2 | 8.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics/*pathology | 2 | 22.0 |
Tumor Stem Cells/chemistry/drug effects/*pathology | 2 | 100.0 |
Thioguanine/administration & dosage | 2 | 22.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 2 | 4.0 |
Bone Marrow/*ultrastructure | 2 | 33.0 |
Leukemia/*classification/immunology/pathology | 2 | 66.0 |
Bone Marrow/chemistry | 2 | 6.0 |
Antigens, Surface/blood | 2 | 9.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 6 | 1.0 |
Leukemia/*diagnosis/immunology | 2 | 33.0 |
Antigens, CD/analysis/*immunology | 3 | 7.0 |
Antigens, Differentiation, Myelomonocytic/analysis/*immunology | 2 | 50.0 |
Scattering, Radiation | 5 | 4.0 |
Histocompatibility Testing | 2 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Immunity, Natural | 2 | 0.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Biological Markers/blood | 2 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Leukemia/drug therapy/*immunology/mortality/pathology | 2 | 100.0 |
Leukemia, Promyelocytic, Acute/*immunology/pathology | 2 | 50.0 |
Multiple Myeloma/*immunology | 2 | 5.0 |
Intercellular Adhesion Molecule-1 | 5 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 12 | 5.0 |
Antigens, CD56 | 3 | 4.0 |
Antigens, CD5 | 2 | 0.0 |
Granulocytes/*immunology | 2 | 5.0 |
Immunoglobulins, Heavy-Chain/*genetics | 5 | 3.0 |
Antigens, CD15 | 6 | 20.0 |
*Bone Marrow Purging | 3 | 12.0 |
Tumor Cells, Cultured/immunology/pathology | 4 | 23.0 |
Antigens, Differentiation, Myelomonocytic/*analysis/immunology | 2 | 100.0 |
Chromosomes, Human, Pair 21/*ultrastructure | 2 | 33.0 |
Chromosomes, Human, Pair 8/*ultrastructure | 2 | 28.0 |
Antigens, CD13 | 19 | 35.0 |
Antigens, CD/*analysis/genetics | 2 | 8.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis/genetics | 2 | 40.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
DNA Nucleotidylexotransferase/analysis | 4 | 20.0 |
Cell Division/*drug effects | 2 | 0.0 |
Leukemia, Myeloid | 2 | 5.0 |
*Hematopoietic Stem Cells/immunology | 3 | 27.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
Megakaryocytes/*pathology | 2 | 6.0 |
Granulocytes/cytology | 2 | 4.0 |
Hemoglobins/biosynthesis | 3 | 18.0 |
Peroxidase/genetics | 2 | 15.0 |
Bone Marrow Purging/*methods | 2 | 5.0 |
Immunotoxins | 3 | 33.0 |
Neoplasms/blood/therapy | 2 | 18.0 |
Lymphocytes/*immunology | 2 | 0.0 |
Colony-Stimulating Factors/*pharmacology | 2 | 4.0 |
Myelodysplastic Syndromes/*genetics | 2 | 2.0 |
Antigens, CD11 | 2 | 2.0 |
Drug Resistance/genetics | 2 | 1.0 |
Antigens, CD44 | 2 | 1.0 |
Hematopoietic Stem Cells/*chemistry | 3 | 11.0 |
Gene Rearrangement/genetics | 3 | 6.0 |
Genes, Immunoglobulin/genetics | 2 | 8.0 |
Lymphocytes/ultrastructure | 2 | 4.0 |
Bone Marrow/enzymology | 2 | 9.0 |
Leukemia, Promyelocytic, Acute | 2 | 3.0 |
Interleukin-6/*pharmacology | 3 | 1.0 |
DNA Probes | 4 | 0.0 |
Proto-Oncogene Proteins/*analysis | 2 | 1.0 |
Regression Analysis | 2 | 0.0 |
Tumor Markers, Biological/*analysis/blood | 4 | 21.0 |
Proto-Oncogene Proteins/*genetics/immunology | 2 | 33.0 |
Antigens, Differentiation, Myelomonocytic/*biosynthesis | 2 | 13.0 |
Complement/immunology | 3 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 3 | 5.0 |
Leukemia, Myelocytic, Acute/*genetics/*immunology | 2 | 100.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Hodgkin Disease/*therapy | 2 | 22.0 |
*Chromosomes, Human, Pair 5 | 2 | 0.0 |
Multiple Myeloma/therapy | 2 | 16.0 |
Sex Factors | 2 | 0.0 |
Frozen Sections | 2 | 2.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
Binding, Competitive | 3 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics/immunology/*pathology | 2 | 100.0 |
Biopsy, Needle | 3 | 0.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
Antibody-Dependent Cell Cytotoxicity | 2 | 2.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Peroxidase/*analysis/immunology | 2 | 50.0 |
Life Tables | 3 | 1.0 |
Tumor Stem Cells/immunology/*pathology | 2 | 40.0 |
Erythropoietin/*pharmacology | 2 | 1.0 |
DNA Nucleotidylexotransferase/metabolism | 2 | 10.0 |
HLA-DR Antigens/metabolism | 2 | 1.0 |
Immunologic Techniques | 4 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols | 2 | 6.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Leukemia/*diagnosis/drug therapy/genetics | 2 | 100.0 |
Peroxidases/metabolism | 2 | 8.0 |
Bone Neoplasms/*pathology | 2 | 10.0 |
Leukemia, Myelocytic, Acute/*immunology/mortality | 2 | 50.0 |
Antigens, CD45 | 2 | 0.0 |
Histocompatibility Antigens/analysis | 2 | 3.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
Hematopoietic Stem Cells/immunology/*pathology | 2 | 10.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Receptors, Antigen, T-Cell/*genetics | 5 | 5.0 |
Antigens, CD1 | 2 | 2.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Receptors, IgG | 2 | 1.0 |
Cell Transformation, Neoplastic/pathology | 2 | 4.0 |
Monocytes/*pathology | 2 | 11.0 |
Epitopes | 2 | 0.0 |
Neprilysin | 6 | 8.0 |
Caspases/*metabolism | 2 | 0.0 |
Chromosome Fragility | 2 | 3.0 |
Cohort Studies | 2 | 0.0 |
Leukemia, Lymphocytic, Acute/*immunology/mortality | 2 | 66.0 |
Antigens, Differentiation/*metabolism | 3 | 2.0 |
Blast Crisis/*genetics/pathology | 2 | 40.0 |
Leukemia, B-Cell, Acute/*immunology | 2 | 33.0 |
Leukemia, Lymphocytic, Acute/immunology/pathology | 2 | 33.0 |
Cell Membrane/chemistry/immunology/ultrastructure | 2 | 100.0 |
Tumor Markers, Biological/immunology | 2 | 11.0 |
Cell Transformation, Neoplastic/drug effects/pathology | 3 | 75.0 |
Staining and Labeling | 3 | 0.0 |
Leukemia/*genetics | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use/immunology | 2 | 8.0 |
Antigens, Neoplasm/analysis/immunology | 2 | 15.0 |
Tumor Markers, Biological/*analysis/immunology | 2 | 16.0 |
Antigens, CD3 | 2 | 0.0 |
B-Lymphocytes | 3 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
Antigens, CD4/*biosynthesis | 4 | 8.0 |
Antigens, CD45/biosynthesis | 2 | 3.0 |
Cluster Analysis | 2 | 1.0 |
Lectins | 2 | 2.0 |
Leukemia/etiology | 2 | 22.0 |
